Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies
Launched by UNIVERSITY OF CYPRUS · Jun 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the genetic factors that contribute to nicotine addiction, which is the addiction to smoking. The goal is to better understand how our genes affect smoking habits and to find new ways to help people quit smoking. Researchers will analyze the DNA of participants to identify potential targets for new treatments. The study will also include a smoking cessation program, where participants will be supported in their efforts to stop smoking while the researchers assess changes in their genetic makeup during the process.
To participate in this trial, you need to be an adult aged 18 to 60 who currently smokes cigarettes daily and is able to understand the study's requirements. Women who join must not be pregnant or breastfeeding. However, individuals with serious health issues, major psychiatric disorders, or those taking specific medications that could impact the study will not be eligible. If you join, you can expect to take part in a program designed to help you quit smoking, along with contributing to valuable research that could help others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-60 years old
- • Current daily cigarette smoker
- • Able to understand study procedures and provide informed consent
- • For females, non-pregnant and non-lactating
- Exclusion Criteria:
- • Presence of significant uncontrolled medical conditions (e.g. cardiovascular disease, respiratory disorders, cancer) that could affect smoking behaviors or study participation
- • Presence of major uncontrolled psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe depression)
- • Current substance use disorder (except nicotine dependence)
- • Taking medications that could significantly interfere with study objectives (e.g. medications for smoking cessation)
- • Significant cognitive impairment that precludes ability to complete study procedures
About University Of Cyprus
The University of Cyprus is a leading academic institution dedicated to advancing research and education in various fields, including biomedical sciences and clinical research. As a clinical trial sponsor, the University of Cyprus leverages its extensive expertise and resources to design, conduct, and oversee clinical studies aimed at improving healthcare outcomes. The university fosters collaboration between researchers, healthcare professionals, and industry partners, ensuring adherence to ethical standards and regulatory requirements. Committed to innovation and excellence, the University of Cyprus plays a pivotal role in translating scientific discoveries into practical applications that benefit patients and communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nicosia, , Cyprus
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported